Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Specific titration schedules are designed to minimize early GI side effects by increasing doses more gradually than in Phase 2
After 28 days, discard the vial regardless of how much solution remains
The LEAD-3 trial assigned patients to randomly receive monotherapies of liraglutide 1.2 mg/day, liraglutide 1.8 mg/day, and glimepiride 8 mg/day (61)
That's normal at this stage, but it's exactly why independent Phase 3 confirmation matters
Regional Growth Trends : North America leads in market share due to the high prevalence of metabolic conditions and strong payer coverage, while AsiaPacific is growing rapidly as healthcare access improves
US$ 29.86
US$ 29.52
US$ 28.81
US$ 24.39
US$ 28.80
US$ 27.41
US$ 22.57
US$ 28.97
